374 related articles for article (PubMed ID: 28705932)
1. Use of a neutralizing antibody helps identify structural features critical for binding of
Kroh HK; Chandrasekaran R; Rosenthal K; Woods R; Jin X; Ohi MD; Nyborg AC; Rainey GJ; Warrener P; Spiller BW; Lacy DB
J Biol Chem; 2017 Sep; 292(35):14401-14412. PubMed ID: 28705932
[No Abstract] [Full Text] [Related]
2. A neutralizing antibody that blocks delivery of the enzymatic cargo of
Kroh HK; Chandrasekaran R; Zhang Z; Rosenthal K; Woods R; Jin X; Nyborg AC; Rainey GJ; Warrener P; Melnyk RA; Spiller BW; Lacy DB
J Biol Chem; 2018 Jan; 293(3):941-952. PubMed ID: 29180448
[No Abstract] [Full Text] [Related]
3. Functional defects in
Gupta P; Zhang Z; Sugiman-Marangos SN; Tam J; Raman S; Julien JP; Kroh HK; Lacy DB; Murgolo N; Bekkari K; Therien AG; Hernandez LD; Melnyk RA
J Biol Chem; 2017 Oct; 292(42):17290-17301. PubMed ID: 28842504
[No Abstract] [Full Text] [Related]
4. Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography.
Orth P; Xiao L; Hernandez LD; Reichert P; Sheth PR; Beaumont M; Yang X; Murgolo N; Ermakov G; DiNunzio E; Racine F; Karczewski J; Secore S; Ingram RN; Mayhood T; Strickland C; Therien AG
J Biol Chem; 2014 Jun; 289(26):18008-21. PubMed ID: 24821719
[TBL] [Abstract][Full Text] [Related]
5. Structural determinants of Clostridium difficile toxin A glucosyltransferase activity.
Pruitt RN; Chumbler NM; Rutherford SA; Farrow MA; Friedman DB; Spiller B; Lacy DB
J Biol Chem; 2012 Mar; 287(11):8013-20. PubMed ID: 22267739
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and Immunological Characterization of Truncated Fragments of the Receptor-Binding Domains of C. difficile Toxin A.
Huang JH; Shen ZQ; Lien SP; Hsiao KN; Leng CH; Chen CC; Siu LK; Chong PC
PLoS One; 2015; 10(8):e0135045. PubMed ID: 26271033
[TBL] [Abstract][Full Text] [Related]
7. Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab.
Hernandez LD; Kroh HK; Hsieh E; Yang X; Beaumont M; Sheth PR; DiNunzio E; Rutherford SA; Ohi MD; Ermakov G; Xiao L; Secore S; Karczewski J; Racine F; Mayhood T; Fischer P; Sher X; Gupta P; Lacy DB; Therien AG
J Mol Biol; 2017 Apr; 429(7):1030-1044. PubMed ID: 28232034
[TBL] [Abstract][Full Text] [Related]
8. Masking autoprocessing of Clostridium difficile toxin A by the C-terminus combined repetitive oligo peptides.
Zhang Y; Hamza T; Gao S; Feng H
Biochem Biophys Res Commun; 2015 Apr; 459(2):259-263. PubMed ID: 25725153
[TBL] [Abstract][Full Text] [Related]
9. Evidence for dual receptor-binding sites in Clostridium difficile toxin A.
Lambert GS; Baldwin MR
FEBS Lett; 2016 Dec; 590(24):4550-4563. PubMed ID: 27861794
[TBL] [Abstract][Full Text] [Related]
10. The combined repetitive oligopeptides of clostridium difficile toxin A counteract premature cleavage of the glucosyl-transferase domain by stabilizing protein conformation.
Olling A; Hüls C; Goy S; Müller M; Krooss S; Rudolf I; Tatge H; Gerhard R
Toxins (Basel); 2014 Jul; 6(7):2162-76. PubMed ID: 25054784
[TBL] [Abstract][Full Text] [Related]
11. Functional properties of the carboxy-terminal host cell-binding domains of the two toxins, TcdA and TcdB, expressed by Clostridium difficile.
Dingle T; Wee S; Mulvey GL; Greco A; Kitova EN; Sun J; Lin S; Klassen JS; Palcic MM; Ng KK; Armstrong GD
Glycobiology; 2008 Sep; 18(9):698-706. PubMed ID: 18509107
[TBL] [Abstract][Full Text] [Related]
12. Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity.
Romano MR; Leuzzi R; Cappelletti E; Tontini M; Nilo A; Proietti D; Berti F; Costantino P; Adamo R; Scarselli M
Toxins (Basel); 2014 Apr; 6(4):1385-96. PubMed ID: 24759173
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for antibody recognition in the receptor-binding domains of toxins A and B from Clostridium difficile.
Murase T; Eugenio L; Schorr M; Hussack G; Tanha J; Kitova EN; Klassen JS; Ng KK
J Biol Chem; 2014 Jan; 289(4):2331-43. PubMed ID: 24311789
[TBL] [Abstract][Full Text] [Related]
14. Sulfated glycosaminoglycans and low-density lipoprotein receptor contribute to Clostridium difficile toxin A entry into cells.
Tao L; Tian S; Zhang J; Liu Z; Robinson-McCarthy L; Miyashita SI; Breault DT; Gerhard R; Oottamasathien S; Whelan SPJ; Dong M
Nat Microbiol; 2019 Oct; 4(10):1760-1769. PubMed ID: 31160825
[TBL] [Abstract][Full Text] [Related]
15. Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B.
Simeon R; Jiang M; Chamoun-Emanuelli AM; Yu H; Zhang Y; Meng R; Peng Z; Jakana J; Zhang J; Feng H; Chen Z
PLoS Biol; 2019 Jun; 17(6):e3000311. PubMed ID: 31233493
[TBL] [Abstract][Full Text] [Related]
16. Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.
Carter GP; Chakravorty A; Pham Nguyen TA; Mileto S; Schreiber F; Li L; Howarth P; Clare S; Cunningham B; Sambol SP; Cheknis A; Figueroa I; Johnson S; Gerding D; Rood JI; Dougan G; Lawley TD; Lyras D
mBio; 2015 Jun; 6(3):e00551. PubMed ID: 26037121
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Clostridium difficile TcdA and TcdB toxins with transition state analogues.
Paparella AS; Aboulache BL; Harijan RK; Potts KS; Tyler PC; Schramm VL
Nat Commun; 2021 Nov; 12(1):6285. PubMed ID: 34725358
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A.
Ho JG; Greco A; Rupnik M; Ng KK
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18373-8. PubMed ID: 16344467
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of Clostridium difficile toxin A.
Chumbler NM; Rutherford SA; Zhang Z; Farrow MA; Lisher JP; Farquhar E; Giedroc DP; Spiller BW; Melnyk RA; Lacy DB
Nat Microbiol; 2016 Jan; 1():15002. PubMed ID: 27571750
[TBL] [Abstract][Full Text] [Related]
20. Autoproteolytic cleavage mediates cytotoxicity of Clostridium difficile toxin A.
Kreimeyer I; Euler F; Marckscheffel A; Tatge H; Pich A; Olling A; Schwarz J; Just I; Gerhard R
Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):253-62. PubMed ID: 21046073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
